FDA Telehealth Warning Letters In early March 2026, the FDA reportedly issued warning letters to multiple telehealth companies regarding compounded GLP-1 marketing practices, with concerns including misleading marketing claims, implications of equivalence with FDA-approved drugs, and obscuring product sourcing
Track your progress in one place with weight logs, injection records, body measurements, calories, water, reminders, progress photos, clothing sizes, weekly check-ins, insights, and shareable reports
If you are wondering whether a prescription path fits your goals, you can take the free assessment quiz
GIP and GLP1, the two incretin hormones: similarities and differences
Reduced Glutathione serve as potential therapeutic agent for several diseases